High Frequency Episodic Migraine Shift to Low Frequency Episodic Migraine in Patients Treated with Galcanezumab

被引：0
|
作者：
Stauffer, Virginia [1 ]
Jedynak, Jakub [1 ]
Gendolla, Astrid [2 ]
Eross, Eric [3 ]
Jin, Leah [4 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Praxis Gendolla, Essen, Germany
[3] Phoenix Headache Inst, Phoenix, AZ USA
[4] Covance Inc, Princeton, NJ USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1772
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Michael Ament
    Kathleen Day
    Virginia L. Stauffer
    Vladimir Skljarevski
    Mallikarjuna Rettiganti
    Eric Pearlman
    Sheena K. Aurora
    The Journal of Headache and Pain, 2021, 22
  • [32] Galcanezumab Safety/tolerability Profile Does Not Differ in Patients with Episodic or Chronic Migraine
    Stauffer, V
    Wang, S.
    Day, K.
    Saper, J. R.
    HEADACHE, 2019, 59 : 45 - 46
  • [33] GalcanezumAb for prevention of high frequency episodic and chronic migraine in the Real Life in ITaly: a multicenter prospective cohort study (the GARLIT study)
    Vernieri, F.
    Altamura, C.
    Brunelli, N.
    Costa, C. M.
    Aurilia, C.
    Egeo, G.
    Fofi, L.
    Favoni, V.
    Pierangeli, G.
    Lovati, C.
    Aguggia, M.
    Bertuzzo, D.
    D'Onofrio, F.
    Doretti, A.
    Di Fiore, P.
    Frediani, F.
    Finocchi, C.
    Rao, R.
    Di Cola, F. Schiano
    Bono, F.
    Ranieri, A.
    Albanese, M.
    Cevoli, S.
    Barbanti, P.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 29 - 30
  • [34] Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
    Lesley J. Scott
    Drugs, 2020, 80 : 893 - 904
  • [35] Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
    Rosen, Noah
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Nagy, Abraham Jim
    HEADACHE, 2019, 59 (04): : 627 - 628
  • [36] Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
    Scott, Lesley J.
    DRUGS, 2020, 80 (09) : 893 - 904
  • [37] Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
    Fabrizio Vernieri
    Claudia Altamura
    Nicoletta Brunelli
    Carmelina Maria Costa
    Cinzia Aurilia
    Gabriella Egeo
    Luisa Fofi
    Valentina Favoni
    Giulia Pierangeli
    Carlo Lovati
    Marco Aguggia
    Florindo d’Onofrio
    Alberto Doretti
    Paola Di Fiore
    Cinzia Finocchi
    Renata Rao
    Francesco Bono
    Angelo Ranieri
    Maria Albanese
    Sabina Cevoli
    Piero Barbanti
    The Journal of Headache and Pain, 2021, 22
  • [38] Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
    Vernieri, Fabrizio
    Altamura, Claudia
    Brunelli, Nicoletta
    Costa, Carmelina Maria
    Aurilia, Cinzia
    Egeo, Gabriella
    Fofi, Luisa
    Favoni, Valentina
    Pierangeli, Giulia
    Lovati, Carlo
    Aguggia, Marco
    d'Onofrio, Florindo
    Doretti, Alberto
    Di Fiore, Paola
    Finocchi, Cinzia
    Rao, Renata
    Bono, Francesco
    Ranieri, Angelo
    Albanese, Maria
    Cevoli, Sabina
    Barbanti, Piero
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [39] Eptinezumab Reduces Migraine Frequency Within the First Month After Treatment in Patients with Episodic or Chronic Migraine
    Winner, Paul
    McAllister, Peter
    Kassel, Eric
    Cady, Roger
    Hirman, Joe
    Biondi, David
    NEUROLOGY, 2019, 92 (15)
  • [40] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low-Versus High-Frequency of Migraine Headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Kathleen A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    NEUROLOGY, 2019, 92 (15)
12345